

E2F8 Antibody (C-Term)

Purified Rabbit Polyclonal Antibody (Pab) Catalog # AP21882b

Product Information

Application Primary Accession Other Accession Reactivity Predicted Host Clonality Isotype	WB, E <u>A0AVK6</u> <u>Q58FA4</u> , <u>F1LMN3</u> Human, Rat, Mouse Mouse, Rat Rabbit polyclonal Rabbit IgG
Isotype	Rabbit IgG
Clone Names	RB54144
Calculated MW	94166

Additional Information

Gene ID	79733
Other Names	Transcription factor E2F8, E2F-8, E2F8
Target/Specificity	This E2F8 antibody is generated from a rabbit immunized with a KLH conjugated synthetic peptide between 835-865 amino acids from human E2F8.
Dilution	WB~~1:2000 E~~Use at an assay dependent concentration.
Format	Purified polyclonal antibody supplied in PBS with 0.09% (W/V) sodium azide. This antibody is purified through a protein A column, followed by peptide affinity purification.
Storage	Maintain refrigerated at 2-8°C for up to 2 weeks. For long term storage store at -20°C in small aliquots to prevent freeze-thaw cycles.
Precautions	E2F8 Antibody (C-Term) is for research use only and not for use in diagnostic or therapeutic procedures.

Protein Information

Name	E2F8
Function	Atypical E2F transcription factor that participates in various processes such as angiogenesis and polyploidization of specialized cells. Mainly acts as a transcription repressor that binds DNA independently of DP proteins and specifically recognizes the E2 recognition site 5'-TTTC[CG]CGC-3'. Directly

represses transcription of classical E2F transcription factors such as E2F1: component of a feedback loop in S phase by repressing the expression of E2F1, thereby preventing p53/TP53-dependent apoptosis. Plays a key role in polyploidization of cells in placenta and liver by regulating the endocycle, probably by repressing genes promoting cytokinesis and antagonizing action of classical E2F proteins (E2F1, E2F2 and/or E2F3). Required for placental development by promoting polyploidization of trophoblast giant cells. Acts as a promoter of sprouting angiogenesis, possibly by acting as a transcription activator: associates with HIF1A, recognizes and binds the VEGFA promoter, which is different from canonical E2 recognition site, and activates expression of the VEGFA gene.

Cellular Location

Nucleus.


Background

Atypical E2F transcription factor that participates in various processes such as angiogenesis and polyploidization of specialized cells. Mainly acts as a transcription repressor that binds DNA independently of DP proteins and specifically recognizes the E2 recognition site 5'-TTTC[CG]CGC-3'. Directly represses transcription of classical E2F transcription factors such as E2F1: component of a feedback loop in S phase by repressing the expression of E2F1, thereby preventing p53/TP53-dependent apoptosis. Plays a key role in polyploidization of cells in placenta and liver by regulating the endocycle, probably by repressing genes promoting cytokinesis and antagonizing action of classical E2F proteins (E2F1, E2F2 and/or E2F3). Required for placental development by promoting polyploidization of trophoblast giant cells. Acts as a promoter of sprouting angiogenesis, possibly by acting as a transcription activator: associates with HIF1A, recognizes and binds the VEGFA promoter, which is different from canonical E2 recognition site, and activates expression of the VEGFA gene.

References

Ota T.,et al.Nat. Genet. 36:40-45(2004). Mural R.J.,et al.Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases. Totoki Y.,et al.Submitted (AUG-2005) to the EMBL/GenBank/DDBJ databases. Christensen J.,et al.Nucleic Acids Res. 33:5458-5470(2005). Logan N.,et al.Oncogene 24:5000-5004(2005).

Images



All lanes : Anti-E2F8 Antibody (C-Term) at 1:2000 dilution Lane 1: A431 whole cell lysate Lane 2: HepG2 whole cell lysate Lysates/proteins at 20 µg per lane. Secondary Goat Anti-Rabbit IgG, (H+L), Peroxidase conjugated at 1/10000 dilution. Predicted band size : 94 kDa Blocking/Dilution buffer: 5% NFDM/TBST.

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.